News
Market and company headlines
BIVIAll
Loading
08:00-10:00Oct 202 Stories
BioVie reports positive Phase 2 Parkinson’s data for bezisterim
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson’s drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological...
BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev., Oct. 20, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of results from the Phase 2 SUNRISE-PD clinical trial evaluating bezi
08:00-15:00Oct 192 Stories
04:00-07:00Oct 192 Stories
MARKETS LIVE: Nasdaq leads Wall Street higher as tech shares recover
4:20pm: Tech shares recover Wall Street ended mixed on Monday as a rebound in technology stocks lifted the S&P 500 and Nasdaq, while the Dow Jones slipped slightly as investors turned their attention to a busy week of corporate earnings. The Dow fell 36 points, or 0.1%, to close at...
BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of
08:00-10:00Oct 142 Stories
BioVie to present Long COVID and Parkinson’s trial results at American Neurological Association meeting
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will present results from two Phase 2 trials of its experimental drug bezisterim, in Long COVID and Parkinson’s disease, at the American Neurological Association’s annual meeting in San Diego. The company said both abstracts were accepted as poster...
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that two abstracts detailing results from the Company’s ADDRESS-LC Phase 2 trial in Long COVID, and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson’s Disease have been accepted for presentation at ANA2026, the annual meeting of the American Neurological Associ
10:00Sep 261 Story
12:00Sep 231 Story
11:00Sep 191 Story
09:00Sep 181 Story
15:00Sep 171 Story
09:00Sep 161 Story
09:00-11:00Sep 152 Stories
BioVie Shares Fall 9.7% After Long COVID Trial Misses Statistical Significance in Full Population
BioVie (NASDAQ:BIVI) shares fell nearly 9. 7% in premarket trading after the company reported results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for neurological symptoms associated with Long COVID.
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid September 15, 2026 8:30 AM EDTCompany...
07:00-09:00Sep 152 Stories
What's Going On With BioVie Stock on Tuesday?
BioVie reported Phase 2 ADDRESS-LC trial results evaluating bezisterim for Long COVID, showing significant subgroup improvements.
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise Bezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall study population An estimated 17–20 million U.S. adults live with Long COVID and currently have no FDA‑approved treatment options Conference call scheduled for 8:30 a.m. today, September 15, 2026, to
12:00-16:00Aug 202 Stories
Top movers analysis one hour before the close of the markets on 2026-08-20: top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
What's going on in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session.
04:00-10:00Aug 202 Stories
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday's regular session. The company's market cap stands at $125.2 million. BioVie (NASDAQ:BIVI) stock rose 30.85%
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Circle8 Group (NASDAQ:CIRC) shares increased by 18.2% to $0.77 during Thursday's pre-market session. The company's market cap stands at $60.1 million. The company's, Q2 earnings came out yesterday.
13:00Aug 191 Story
02:00-14:00Aug 132 Stories
These stocks have an unusual volume in today's session
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
BioVie Q4 EPS $(0.70) Up From $(1.42) YoY
BioVie (NASDAQ:BIVI) reported quarterly losses of $(0.70) per share. This is a 50.7 percent increase over losses of $(1.42) per share from the same period last year.
15:00-18:00Aug 122 Stories
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design August 12, 2026 4:15 PM EDTCompany ParticipantsCuong Viet...
Let's take a look at the stocks that are in motion in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
12:00-15:00Aug 122 Stories
These stocks are the most active in today's session
Discover the most active stocks in Wednesday's session. Stay informed about the stocks that are generating the most trading volume!
Here are the top movers in Wednesday's session.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.